Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma - Concepedia

Concepedia

Publication | Open Access

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

DOI Full Paper Access

1.6K

Citations

18

References

2008

Year

Teri Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A. Butman, Kevin Camphausen,

Journal of Clinical Oncology

Abstract

We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.

References

	Year	Citations

Page 1